Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

This publication has 34 references indexed in Scilit:

• Inflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
  Biological Psychiatry, 2009
• Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
  Published by Elsevier ,2008
• Concerns of former breast cancer patients about disease recurrence: a validation and prevalence study
  Psycho‐Oncology, 2008
• Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
  The Lancet, 2008
• The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease
  Health and Quality of Life Outcomes, 2008
• Prevalence and correlates of suicidal ideation among patients with skin disease
  Journal of the American Academy of Dermatology, 2006
• Depression in dermatological patients identified by the Mini International Neuropsychiatric Interview questionnaire
  Journal of the American Academy of Dermatology, 2006
• Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis
  British Journal of Dermatology, 2005
• Current severe psoriasis and the Rule of Tens
  British Journal of Dermatology, 2005
• The Hospital Anxiety and Depression Scale
  Acta Psychiatrica Scandinavica, 1983